Navigation Links
Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
Date:8/7/2012

SAN FRANCISCO, Aug. 7, 2012 /PRNewswire/ -- Adynxx, a clinical stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today the completion of enrollment in the Phase 1 clinical study in healthy volunteers of its lead investigational drug candidate for the prevention of acute and chronic post-surgical pain, AYX1.

"The Adynxx therapeutic platform – a novel approach to treating and preventing pain – has the potential to transform pain management," said Dennis Podlesak, chairman of the Adynxx board of directors. "The clinical development of this breakthrough technology is being driven by an accomplished management team that has a track record of success that includes building successful biotech companies and attaining multiple new drug approvals. The Adynxx team is well positioned to achieve our goal of developing these exciting new treatment options for preventing pain."

The 30 subject, dose-escalating study is currently evaluating AYX1 in five cohorts of healthy volunteers. Later this year, Adynxx plans to move into a proof-of-concept Phase 2 clinical study assessing the ability of a single administration of AYX1 at the time of surgery to reduce acute pain, prevent the transition to persistent post-surgical pain and consequently improve functional recovery.

"Despite many years of investigation and development, effective relief of post-surgical pain remains a challenge for the millions of patients who undergo surgery every year," said Rick Orr, president and chief executive officer of Adynxx. "Given the urgent need for new treatment options for post-surgical pain, we are excited to have advanced the AYX1 development program at such a rapid pace since the company's founding.  With enrollment complete, we look forward to receiving and evaluating the unblinded safety data later this quarter.  This will allow us to initiate a Phase 2 efficacy stud
'/>"/>

SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HeartWare Completes Acquisition Of World Heart Corporation
2. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
3. Hologic Completes Acquisition Of Gen-Probe
4. United Seating & Mobility Completes Acquisition of Active American Mobilitys Rehab Division
5. United Seating & Mobility Completes Acquisition of Active American Mobility
6. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
7. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
8. Henry Schein Completes Three Acquisitions To Advance Strategic Plan
9. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
10. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
11. Ultra Clean Holdings, Inc. Completes Strategic Merger with Advanced Integration Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... France , Dec. 19, 2014  Eli Lilly ... (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide ... as BioChaperone Lispro, for treatment in people with type ... Adocia,s proprietary BioChaperone® technology and is currently in Phase ... BioChaperone Lispro with the goal of optimizing glucose levels ...
(Date:12/17/2014)... DIEGO , Dec. 17, 2014 Royal ... Volcano Corporation (NASDAQ: VOLC ), a global leader ... announced that they have entered into a definitive merger agreement. ... to acquire all of the issued and outstanding shares of ... purchase price of USD 1 billion (approx. EUR 800 million), ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... Cellular Dynamics International (CDI) ... Endothelial Cells for use in vascular-targeted drug discovery, ... Endothelial cells make up the lining of blood ... research across a multitude of disease states.  Endothelial dysfunction ...
... Eli Lilly and Company (NYSE: LLY ... of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic acid ... remodeling in transiliac crest bone biopsies from postmenopausal women ... presentation at the 2011 Annual Meeting of the American ...
Cached Medicine Technology:Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 2Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 3Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 4New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 2New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 3New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 4New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 5New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 6New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 7
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
(Date:12/22/2014)... The NLN’s 2015 Leadership Institute ... month. Faculty have been selected through competitive application ... for administrative leadership roles within their academic institutions; ... Educators, featuring a curriculum uniquely devised for up-and-comers ... , Twenty nurse educators were chosen for the ...
(Date:12/21/2014)... 22, 2014 Weddingshe.com, an outstanding online ... has recently released its new selection of Cocktail Dresses ... made according to the newest fashion trends. ... dresses for cocktail parties . All of them are ... off. We are making every effort to offer a ...
(Date:12/21/2014)... New York (PRWEB) December 21, 2014 ... and other product liability claims involving a class ... mimetics continue to move forward in a federal ... Southern District of California, Bernstein Liebhard LLP reports. ... Court has established a data cut-off date of ...
(Date:12/21/2014)... December 21, 2014 Serious Buyer, Andrew ... 1967 Jm Morrison and the Doors International Ballroom at ... would also be the only time that Morrison's mother ... on Nov. 25, 1967. According to Hawley, “This would ... did play the Alexandria Roller Rink earlier that year ...
Breaking Medicine News(10 mins):Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4
... Prime Healthcare Services,("Prime Healthcare"), has acquired ... Center from Tenet Healthcare Corporation,("Tenet") effective June ... Encino Hospital,Medical Center. Prime Healthcare also has ... additional Tenet hospitals in California --,167-bed Garden ...
... LONDON, June 2 , - Misys Trade ... Misys plc (FTSE: MSY.L), the global application ... been awarded the double accolade of,winning two SWIFTReady ... solutions., Having been the first trade services ...
... Bunk bed-related injuries are not an issue of ... a study conducted by investigators at the Center for ... Nationwide Childrens Hospital. The study, published in the June ... who sustain bunk bed-related injuries are younger than 10 ...
... baseball-related injuries has decreased within the last 10 years, ... to a new study conducted by researchers at the ... Research Institute at Nationwide Children,s Hospital. During the two-year ... occurred with an injury rate of more than one ...
... medical center, new channel hosted exclusively by doctors, available 24/7 to listeners ... ... ... Radio, features daily shows and reports on general health and, wellness, plastic surgery, ...
... into the toxins, virulence, spread and prevention of the ... issue of the Journal of Medical Microbiology. These findings ... ammunition in the fight against a sometimes deadly pathogen. ... is most common in hospitals. It can cause a ...
Cached Medicine News:Health News:Prime Healthcare Services to Acquire Three Hospitals from Tenet Healthcare Corporation 2Health News:Misys Wins Prestigious Gold Labels From SWIFT for Entire Trade Services Solutions Portfolio 2Health News:Bunk beds pose dangers to kids and adults 2Health News:Bunk beds pose dangers to kids and adults 3Health News:Injuries to high school baseball players becoming more serious 2Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 2Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 3Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 4Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 5Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 6Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 7Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 8Health News:Advances in C. difficile research 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: